Big Pharma’s $1Bn Antibiotic Development Fund Offers ‘Breathing Room’ For Reimbursement Fix

Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.

AMR Action Fund Launch CEOs
Big pharma is providing $1bn to support antibiotic clinical research • Source: Screen shot of AMR Action Fund launch

Big pharma companies are putting their muscle behind a new initiative to help smaller entities get antibiotics through the pipeline. But they acknowledge the effort will be futile without reimbursement reform and other measures to help companies survive once they get a product on the market.

CEOs from Eli Lilly and Company, Merck & Co., and Pfizer Inc. were part of a 9...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category